KLRC1 and neoplasm: At present, the exact mechanism behind this benefit is unclear and interestingly, may not involve endogenous NK cells but instead the direct interaction of tumor cell Qa-1b and CAR-T expressed NKG2A, resulting in resistance to CAR-T therapy.